Literature DB >> 16424584

Validation of a personalized dosimetric evaluation tool (Oedipe) for targeted radiotherapy based on the Monte Carlo MCNPX code.

S Chiavassa1, I Aubineau-Lanièce, A Bitar, A Lisbona, J Barbet, D Franck, J R Jourdain, M Bardiès.   

Abstract

Dosimetric studies are necessary for all patients treated with targeted radiotherapy. In order to attain the precision required, we have developed Oedipe, a dosimetric tool based on the MCNPX Monte Carlo code. The anatomy of each patient is considered in the form of a voxel-based geometry created using computed tomography (CT) images or magnetic resonance imaging (MRI). Oedipe enables dosimetry studies to be carried out at the voxel scale. Validation of the results obtained by comparison with existing methods is complex because there are multiple sources of variation: calculation methods (different Monte Carlo codes, point kernel), patient representations (model or specific) and geometry definitions (mathematical or voxel-based). In this paper, we validate Oedipe by taking each of these parameters into account independently. Monte Carlo methodology requires long calculation times, particularly in the case of voxel-based geometries, and this is one of the limits of personalized dosimetric methods. However, our results show that the use of voxel-based geometry as opposed to a mathematically defined geometry decreases the calculation time two-fold, due to an optimization of the MCNPX2.5e code. It is therefore possible to envisage the use of Oedipe for personalized dosimetry in the clinical context of targeted radiotherapy.

Entities:  

Mesh:

Year:  2006        PMID: 16424584     DOI: 10.1088/0031-9155/51/3/009

Source DB:  PubMed          Journal:  Phys Med Biol        ISSN: 0031-9155            Impact factor:   3.609


  7 in total

1.  Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours.

Authors:  Phillip G Claringbold; Paul A Brayshaw; Richard A Price; J Harvey Turner
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-10-30       Impact factor: 9.236

Review 2.  Three-dimensional radiobiological dosimetry (3D-RD) with 124I PET for 131I therapy of thyroid cancer.

Authors:  George Sgouros; Robert F Hobbs; Francis B Atkins; Douglas Van Nostrand; Paul W Ladenson; Richard L Wahl
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-04-12       Impact factor: 9.236

Review 3.  Three-dimensional imaging-based radiobiological dosimetry.

Authors:  George Sgouros; Eric Frey; Richard Wahl; Bin He; Andrew Prideaux; Robert Hobbs
Journal:  Semin Nucl Med       Date:  2008-09       Impact factor: 4.446

4.  Development and Validation of RAPID: A Patient-Specific Monte Carlo Three-Dimensional Internal Dosimetry Platform.

Authors:  Abigail E Besemer; You Ming Yang; Joseph J Grudzinski; Lance T Hall; Bryan P Bednarz
Journal:  Cancer Biother Radiopharm       Date:  2018-04-25       Impact factor: 3.099

5.  Three-dimensional radiobiologic dosimetry: application of radiobiologic modeling to patient-specific 3-dimensional imaging-based internal dosimetry.

Authors:  Andrew R Prideaux; Hong Song; Robert F Hobbs; Bin He; Eric C Frey; Paul W Ladenson; Richard L Wahl; George Sgouros
Journal:  J Nucl Med       Date:  2007-05-15       Impact factor: 10.057

6.  Abdo-Man: a 3D-printed anthropomorphic phantom for validating quantitative SIRT.

Authors:  Jonathan I Gear; Craig Cummings; Allison J Craig; Antigoni Divoli; Clive D C Long; Michael Tapner; Glenn D Flux
Journal:  EJNMMI Phys       Date:  2016-08-05

7.  Comparison of commercial dosimetric software platforms in patients treated with 177 Lu-DOTATATE for peptide receptor radionuclide therapy.

Authors:  Erick Mora-Ramirez; Lore Santoro; Emmanuelle Cassol; Juan C Ocampo-Ramos; Naomi Clayton; Gunjan Kayal; Soufiane Chouaf; Dorian Trauchessec; Jean-Pierre Pouget; Pierre-Olivier Kotzki; Emmanuel Deshayes; Manuel Bardiès
Journal:  Med Phys       Date:  2020-07-31       Impact factor: 4.071

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.